ISPOR Releases Top 10 HEOR Trends Report for 2022-2023

By HEOR Staff Writer

January 17, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a renowned professional society in Health Economics and Outcomes Research (HEOR). Biennially, it publishes a report, outlining the ISPOR Top 10 HEOR Trends. This article explores the 2022-2023 top trends, heavily influenced by the COVID-19 pandemic, and their implications for the healthcare industry.

Real-world Evidence (RWE) – The Number One Trend

RWE has been identified as the top trend for 2022-2023. Its significance has grown due to its crucial role in addressing the pandemic. Health data, which is integral to RWE, also joins the trends list at number nine.

Health Equity – A New Entrant in the Top Trends

The pandemic has starkly highlighted health disparities and their devastating impact. As a result, health equity has emerged as a top trend, ranking third on the list.

Public Health and Health Technology Assessment (HTA) – Rising Trends

Public health has also been elevated in the trends list, ranking seventh, no doubt due to the pandemic’s impact. HTA enters the list at number eight, underlining the importance of evaluating healthcare interventions.

Artificial Intelligence – A Key Player in the Top Trends

Artificial Intelligence (AI) has made its mark, joining the top trends at number ten. It’s clear that healthcare data and AI are becoming increasingly intertwined, driving innovation and efficiency in the sector.


These top trends in HEOR provide valuable insights for all healthcare stakeholders, from researchers and academicians to life sciences industry professionals and patients. They highlight the importance of informed health decisions backed by rigorous, proven methodologies.

 

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
USTR Germany Pharma Investigation
USTR Germany Pharma Investigation and its Impact on Global Drug Pricing

By João L. Carapinha

June 19, 2026

The USTR Germany Pharma Investigation has exposed how Germany’s pharmaceutical reimbursement policies force American patients to finance a disproportionately large share of worldwide drug research and development. By systematically suppressing prices below sustainable levels, these practices erod...